Inhaled therapy is determined by the needs of individual therapeutic interventions. Inhalation therapy has been used for thousands of years in many forms and applications. Inhaler design has remained mostly unchanged over the last decade; however some aspects have resulted in advancements that provide new disease treatment options. The structure and design of an inhaler have a significant impact on the quantity of aerosol that is deposited in the lungs. An ideal inhaler should deliver precise and regular doses to a specific area of the lungs whilst maintaining drug stability. It's also ideal if the devices are compact and simple enough for patients to operate.
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, University of Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Shree S.K.Patel College of Pharmaceutical Education and Research, India
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Pro and con to dermpharm and tox assays- 2023
Howard I Maibach, University of California, United States
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : Pediatric brain on cannabinoids: Adverse effects of cannabinoid products in children and adolescents
Peter B Chase, Essentia Health- St. Mary's Medical Center, United States
Title : EBV latent membrane protein 1 augments gammer-delta T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules
Yue liu, Hong Kong Baptist University, China